Evaluation of perinatal and intrafamilial hepatitis B prevention programmes in a well child clinic: 9-year follow-up study in Turkey.

Evaluating the performance of well child clinics on adherence to recommended perinatal hepatitis B prevention programmes as well as assessing the outcome of infants living with hepatitis B surface antigen (HBsAg)-positive parents is important. A retrospective study was performed of 336 babies who had at least one HBsAg-positive parent and were followed-up in the well child clinic of Gazi University Hospital (Ankara, Turkey) between 2001 and 2009. Rates of passive immunisation in 109 babies with HBsAg-positive mothers and initiation of hepatitis B vaccination of all 336 babies with HBsAg-positive parents were 98.8% and 100% respectively. Ninety-two babies (27.4%) were lost to follow-up before completing primary immunisation. The recommended perinatal hepatitis B prevention programme was performed successfully in 194 of the 306 infants who were old enough for post-vaccination serotesting (63.4%). One baby became HBsAg-positive, and 88.1% of babies were seroprotected. Hepatitis B surface antibody (anti-HBs) levels were found to be increased if the HBsAg-positive parent was the father. There was a negative correlation between serotesting time and anti-HBs titres. The study infants had a total of 187 siblings and 123 (65.8%) were serotested after completing primary immunisation with 108 found to be seropositive. Although the vaccination rate in the perinatal hepatitis B prevention programme is satisfactory, post-vaccination serotesting and evaluation of infants and their siblings are still deficient.

Immunogenicity of recombinant hepatitis B vaccine: comparison of two different vaccination schedules.

BACKGROUND: Neonatal immunization with hepatitis B (HB) vaccine induces protective levels of antibody (anti-HBs > or =10 IU/L) in a majority of vaccines. However, the duration of protection after HB vaccination in infants is unknown. A smaller proportion of children vaccinated beginning at birth with three doses of HB vaccine were found to have protective titers 5-10 years after initial vaccination. Long-term efficacy of HB vaccine depends mainly on peak antibody levels after vaccination, and subjects were observed to have lower levels of antibodies if they received the first dose of vaccine immediately after birth. The aim of our study was to compare the immunogenicity of two different HB vaccine schedules in infants born to HB surface antigen-negative mothers. METHODS: Anti-HBs titers in infants vaccinated with two different schedules were compared. Infants were vaccinated at 0, 2, and 9 months (group 1) or at 2, 4, and 9 months (group 2). In total, 267 blood samples were analyzed at a mean of 14.20 +/- 2.39 months after the third vaccine dose. Sera were tested for hepatitis B surface antigen (HBsAg), hepatitis B surface antibody (anti-HBs), and hepatitis B core antibody (anti-HBc) using commercial enzyme immunoassay kits. RESULTS: The geometric mean titers for anti-HBs were 95.00 and 379.51 IU/L and the rates of anti-HBs more than > or =100 IU/L were 57.7 and 94.9% in group 1 and 2 infants, respectively. CONCLUSION: Delaying the first dose of the HB vaccine until 2 months after birth produces a higher immune response and can provide longer term protection.

Hepatitis E virus seroepidemiology and its change during 1 year in primary school students in Ankara, Turkey.

The Hepatitis E virus (HEV) is widespread throughout the world. The purpose of this study was to evaluate the time-related change of antibody levels against Hepatitis E in primary school children. In this cross sectional study, the samples of 515 students were examined at two times. The mean age of the students was 7(6-13) years. The seroprevalences of anti-HEV were 1.7% and 2.1% at the first and second visits respectively. There was no statistically significant differences between anti-HEV seropositivity and the parents' education and employment status (p >0.05). This serosurvey shows that there is not a high prevalence of enterically transmitted viral hepatitis in Ankara, Turkey, which is a situation similar to developed countries.